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INTRODUCTION
CONCLUSION
• The nation’s health care agenda is focused on 
achieving the “Triple Aim” to improve quality of care, 
the health of the population, and simultaneously 
reduce cost. 
• Managed Care (MC) has become the backbone of 
care delivery for Medicaid programs, the national 
health insurance program available to individuals 
with low income. In 2019, 18% of the population in 
PA (2.3 million individuals) were Medicaid enrollees.
• One intervention being utilized by PA’s Medicaid MC 
program to achieve the Triple Aim is Pay for 
Performance (P4P). While P4P is a favorite among 
policymakers, its effectiveness in improving health 
outcomes is still under investigation. 
• Study Aim: To evaluate the role of P4P in improving 
provider performance within PA’s HealthChoices
Medicaid MC Program. 
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• Overall, six measures demonstrated an increased performance while two measures declined. The increased performance 
by insurers, paired with the increased performance on outcome measures bolsters the likelihood that pay for performance 
(P4P) has a positive influence on the HealthChoices program. 
• Considering that the maximum percent total revenue was 1.44% in 2016, the magnitude of the incentives may not be 
driving the improvements. Future research should explore the mechanism for improvement, including the possibility that 
P4P is increasing provider awareness which may be responsible for improved performance. 
• While the current study examined individual measures, opportunities exist to consider bundled measures that focus on a 
disease approach rather than on individual procedures. A "disease" or "population" approach to incentives would allow 
clinicians to focus more broadly on meaningful outcomes rather than single measures. This in turn could enhance patient 
experience and improve quality of care.
• Future improvements on the P4P approach may include ongoing conversations with providers to determine ways in which 
insurers and providers can work collaboratively for improved population health.
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Fig.2 Number of enrollees in each insurance provider. Percentage 
reflects percent of total Medicaid population enrolled.
➢ NW – Aetna, AmeriHealth, Gateway, UPMC
➢ NE – Aetna, AmeriHealth-NE, Geisinger
➢ SW – Aetna, Gateway, United, UPMC
➢ LC – Aetna, AmeriHealth, Gateway, United, UPMC
➢ SE – Aetna, Keystone, Health Partners, United
Fig.1 Map of Pennsylvania separated by HealthChoices coverage areas. 
Color gradient represents population in thousands enrolled in Medicaid 
while county numbers indicate percent of population enrolled in Medicaid 
out of total population.
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METHODS
Data Acquisition
➢ HealthChoices provided annual performance
outcomes for 11 insurers across 16 measures 
collected between 2011 and 2016
➢ Retrospective longitudinal analysis using SAS v.9.4
Research Question 1
➢ Did P4P effectively incentivize insurance providers 
to obtain better performance outcomes between the 
years of 2012 and 2016?
Analysis
➢ Six performance outcomes compared to inflation-
adjusted incentive payouts across seven insurance 
providers (Aetna, AmeriHealth, Gateway, Health 
Partners, Keystone, United, UPMC)
➢ SEM proposed to test overall effect of incentives on 
performance outcomes.
Fig.3 Model depicting casual relationship between performance outcomes 
(PO) and incentive payouts (IP) over time (1-5). Serially correlated error 
terms (e1-e4) account for the time-dependent relationship.
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Table 2 Measures selected for Diabetes, Maternal, and Cancer 
Screening care groups
Outcome Measure
ADV Annual Dental Visits
AWC Adolescent Well-Care Visits
CBP Controlling High Blood Pressure
CDC_Hb Comp. Diabetes Monitoring: HbA1c Poor Control
FPC Frequency of Prenatal Care: >= 81%
PPC_1tri Prenatal Care in 1st Trimester
Research Question 2
➢ Can any measures be grouped together to develop 
more holistic performance targets for insurers?
Analysis
➢ Three care groups created including all insurers
➢ Pearson correlations computed for all variables
RESULTS 1
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Fig. 4 Between 2012 and 2016 four out of six performance measures improved including controlling high blood 
pressure, comprehensive diabetes monitoring, prenatal care in the first trimester and annual dental visits. 
Performance on frequency of prenatal care and adolescent well care visits declined slightly
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Fig. 5 Between 2012 and 2016 six providers improved their performance as measured by benchmark outcomes. 
Health Partners was the strongest performer. By contrast, Gateway’s performance declined potentially effecting 
more than 280,000 individuals. 
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Fig. 6 Total pay-outs increased from 2012 to 2016 
(controlling for inflation) except for Adolescent well care 
visits. Maximum PTR in 2016 = 1.44%.
RESULTS 2
Performance 
Percentiles
Diabetes correlations Plan r p
CDC_Hb MAN
PA weighted average r(7) = -.85 < .05
Aetna r(7) = -.90 < .01
Health Partners r(7) = -.82 < .05
United r(7) = -.80 < .05
CDC_Hb CDC_LDL
Gateway r(4) = -.97 < .05
United r(4) = -.98 < .05
EED Man
AmeriHealth-NE r(4) = .98 < .05
Geisinger r(4) = .99 < .01
Maternal correlations Plan r p
FPC PPC_1tri
PA weighted Average r(6) = .94 < .01
Gateway r(7) = .90 < .01
Health Partners r(7) = .86 < .05
Keystone r(7) = .92 < .01
PPC
PPC_1tri
Gateway r(7) = .82 < .05
Health Partners r(7) = .76 < .05
AWC
Gateway r(7) = .89 < .01
Health Partners r(7) = .88 < .01
Keystone r(7) = -.82 < .05
W34
AWC AmeriHealth r(7) = .88 < .01
W15 United r(7) = .80 < .05
* All other measures significantly correlated for Health Partners
Screening correlations Plan r p
BCS CCS
Gateway r(7) = -.76 < .05
Health Partners r(7) = .90 < .01
Table 3 In the maternal care group, FPC was significantly correlated with 
PPC_1tri at the State level. This effect was also observed within Health Partners, 
Gateway, and Keystone insurance providers. All other correlations were 
significant for Health Partners. Within the Gateway health plan, PPC_1tri was 
also significantly correlated with PPC. Moreover, PPC was correlated with AWC. 
Keystone had significant negative correlation between PPC and AWC. For United 
and AmeriHealth plans, W34 was correlated with W15 and AWC, respectively. 
Table 4 For diabetes care, a significant negative correlation was identified between 
CDC_Hb and MAN at the State level as well as for Aetna, Health Partners, and 
United insurers. Hb was also negatively correlated with LDL control <100. These 
correlations were evident in Gateway and United health plans. EED and MAN were 
positively correlated for AmeriHealth-NE and Geisinger health plans.
Table 5 In the cancer screening group, BCS and CCS was negatively correlated 
for Gateway. By contrast, BCS and CCS were positively correlated for Health 
Partners. Gateways performance wavered while Health Partners was consistent 
over time.
Table 1 Abbreviations for 6 outcome measures.
Care Group Outcome Measure
Maternal
AWC Adolescent Well-Care Visits
FPC Frequency of Prenatal Care: >= 81%
PPC Postpartum Care
PPC_1tri Prenatal Care in 1st Trimester
W15 Well Child Visits in the First 15 Mos. Of Life (6 or more)
W34 Well Child Visits in 3rd, 4th, 5th & 6th Years of Life
Diabetes
CDC_Hb Comp. Diabetes Monitoring: HbA1c Poor Control
CDC_LDL Comp. Diabetes Monitoring: LDL Control < 100
EED Eye Exam for Patients with Diabetes
MAN Comp. Diabetes Monitoring: Medical Attention for Nephropathy
Cancer
Screening
BCS Breast Cancer Screening
CCS Cervical Cancer Screening
